Marker Therapeutics Inc (MRKR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Marker Therapeutics Inc (MRKR) has a cash flow conversion efficiency ratio of -0.149x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.74 Million) by net assets ($18.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Marker Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Marker Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MRKR total liabilities for a breakdown of total debt and financial obligations.
Marker Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Marker Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UMS Holdings Bhd
KLSE:7137
|
0.018x |
|
Vereinigte Filzfabriken AG
MU:VFF
|
N/A |
|
OURGAME INT.HOL.DL-00005
F:13O
|
N/A |
|
Salee Colour Public Company Limited
BK:COLOR
|
0.017x |
|
Aurora Labs Ltd
AU:A3D
|
-1.442x |
|
Agung Semesta Sejahtera Tbk PT
JK:TARA
|
-0.002x |
|
Tandy Leather Factory Inc
NASDAQ:TLF
|
-0.019x |
|
Muar Ban Lee Group Bhd
KLSE:5152
|
-0.038x |
Annual Cash Flow Conversion Efficiency for Marker Therapeutics Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Marker Therapeutics Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see MRKR company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $18.56 Million | $-10.91 Million | -0.588x | +49.75% |
| 2023-12-31 | $14.05 Million | $-16.44 Million | -1.170x | +14.98% |
| 2022-12-31 | $19.60 Million | $-26.97 Million | -1.376x | -121.87% |
| 2021-12-31 | $43.99 Million | $-27.28 Million | -0.620x | +15.35% |
| 2020-12-31 | $27.34 Million | $-20.03 Million | -0.733x | -76.66% |
| 2019-12-31 | $44.09 Million | $-18.28 Million | -0.415x | -69.97% |
| 2018-12-31 | $59.34 Million | $-14.48 Million | -0.244x | +89.42% |
| 2017-12-31 | $3.66 Million | $-8.44 Million | -2.307x | -119.17% |
| 2016-12-31 | $6.18 Million | $-6.51 Million | -1.053x | -617.66% |
| 2015-12-31 | $-21.36 Million | $-4.34 Million | 0.203x | -90.48% |
| 2014-12-31 | $-1.02 Million | $-2.19 Million | 2.137x | +2597.17% |
| 2013-12-31 | $-8.77 Million | $-694.58K | 0.079x | -71.32% |
| 2012-12-31 | $-5.67 Million | $-1.57 Million | 0.276x | -27.04% |
| 2011-12-31 | $-3.46 Million | $-1.31 Million | 0.379x | +33.91% |
| 2010-12-31 | $-3.27 Million | $-925.04K | 0.283x | -84.14% |
| 2009-12-31 | $-629.39K | $-1.12 Million | 1.782x | +654.23% |
| 2008-12-31 | $-3.02 Million | $-714.42K | 0.236x | -67.71% |
| 2007-12-31 | $-1.67 Million | $-1.23 Million | 0.732x | +85.14% |
| 2006-12-31 | $-3.00 Million | $-1.19 Million | 0.395x | -24.67% |
| 2005-12-31 | $-2.22 Million | $-1.16 Million | 0.525x | +5.38% |
| 2004-12-31 | $-2.44 Million | $-1.21 Million | 0.498x | -87.63% |
| 2003-12-31 | $-643.75K | $-2.59 Million | 4.026x | +233.30% |
| 2002-12-31 | $465.83K | $-1.41 Million | -3.020x | -292.90% |
| 2000-12-31 | $-561.95K | $-879.74K | 1.566x | -72.84% |
| 1999-12-31 | $-141.42K | $-815.18K | 5.764x | -- |
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-assoc… Read more